Advertisement
Advertisement
U.S. Markets close in 3 hrs 35 mins
Advertisement
Advertisement
Advertisement
Advertisement

Rigel Pharmaceuticals, Inc. (RIGL)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
1.4450-0.0650 (-4.30%)
As of 12:25PM EDT. Market open.
Advertisement

Yahoo Finance will soon be upgrading our Conversations message board platform to provide a better experience for our users. Only comments published since April 21, 2021 will be visible on Yahoo Finance after the upgrade. If you wish to download and save any of your older comments, please submit a request via the Privacy Dashboard by no later than Aug. 15, 2022.

Sign in to post a message.
  • S
    Stehouwer
    This site just sent me a 68% winner. (http://traderspot.club)
  • d
    dudley dowrong
    Strong finish.
  • j
    josh
    8/3/22
    Cantor Fitzgerald Raises Price Rigel Pharmaceuticals, Inc. (RIGL) $1.00 -> $2.00 Neutral
  • D
    D
    Yet again, the only good thing about this morning's plummeting price is that the volume is staying moderately low.
  • R
    Redposition
    Great results !
  • j
    josh
    RIGEL REPORTS SECOND QUARTER 2022 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE

    Q2 TAVALISSE NET PRODUCT SALES OF $18.6 MILLION AND TOTAL REVENUES OF $29.8 MILLION

    Q2 LOSS PER SHARE $0.08

    Q2 EARNINGS PER SHARE VIEW $-0.12, REVENUE VIEW $23.7 MILLION
  • M
    MBMoney
    One opportunity that Rigel hasn't made much mention of, but perhaps will end up being a key component to revenue growth, relates to milademetan. Rigel initially licensed this to Daiichi-Sankyo, which out-licensed it to Rain Therapeutics. These guys are clearly on the move, and have high expectations for the drug. Here is some info from today's press release from Rain Therapeutics: Rain Therapeutics Inc. (NasdaqGS: RAIN), (Rain), a late-stage biotechnology company developing precision oncology therapeutics, today announced completion of enrollment in its Phase 3 MANTRA randomized, global, registrational trial of its lead product candidate, milademetan, an oral, small molecule inhibitor of the MDM2-p53 complex that reactivates p53. The trial targeted an enrollment of160 patients and completed enrollment five months ahead of schedule with 175patients. The MANTRA trial is evaluating milademetan compared to an approved standard of care in patients with well-differentiated /dedifferentiated (WD/DD) liposarcoma (LPS) that have progressed on at least one prior systemic therapy including an anthracycline. MANTRA is an event-driven trial with progression-free survival (PFS) as the primary endpoint, which will be analyzed upon reaching 105 events. The MANTRA trial is powered to show a doubling of PFS versus the standard of care.

    "We are excited to have achieved a milestone in our milademetan clinical program. We believe the rapid enrollment in MANTRA reflects a patient population in LPS that may be larger than expected, and that exhibits a significant unmet medical need,” said Avanish Vellanki, co-founder and chief executive officer of Rain.
  • M
    MBMoney
    Analysts are projecting EPS of -$0.12. It will be interesting to see if the company can beat this expectation, but it's hard to anticipate that they will, given how poorly the management team has run things thus far. In Q1, they shipped a total of 1824 bottles of Tavalisse, representing net product sales of $16.2 million. In Q2 2021, they shipped a total of 1905 bottles, representing net product sales of $17.1 million, so we will also learn how well they do Y/Y for Q2. I would assume they will need to say something about the Knight Therapeutics deal that was completed in Q2, but since they kept quiet about it, we will more than likely need to back into the amount of up-front cash Knight paid. Further, the company had cash, cash equivalents, and short-term investments totaling $107.5 million as of March 31st, so we will want to keep our eye on the cash burn.

    No confidence on my end, but since literally everything has gone wrong this year, perhaps shareholders are due for some form of good news on Tuesday. If the news is negative, the board of directors will need to get out of bed and start acting in the best interest of shareholders.
  • S
    Steve
    A commercial deal?!?!
  • K
    King David
    OVER 12 MILLION SHARES SHORT. LOOKING FOR OVER $3.00 IMMEDIATELY, OVER $5.00 WITH IN A MONTH. THIS IS GOING TO BE FUN.
    Bullish
  • *
    ****
    Why is this up 7%, somebody know something?? Maybe good news today..
  • M
    MBMoney
    I've posted on more than one occasion that I have no confidence in the management team, or board of directors, of this company. The 2022 results have been nothing but catastrophic for shareholders, and it appears that the two 'catalysts' for moving the company forward near-term may be dead in the water. Yet, in the past two days, the company has posted for a Senior Clinical Data Manager, and a Senior Medical Director, both in San Francisco. Thus, either the company is totally 'IN' on its future success, or the management team is a complete fiasco. Logic would seem to suggest that the writing on the wall is that the company anticipates good things, but we clearly need to get beyond Tuesday's call to see what the story is. If that earnings call is a disaster, shareholders need to push for a massive change in leadership. Let's hope the company isn't being led by a bunch of non-performers.
  • G
    Gavin
    Anyone notice the RIGL 8-k indicating they are suing to protect their patent?
  • g
    gumax
    short every pump;
    this stock is rigged by 2-3 Institutional Holdings that makes money with options plays
    Bearish
  • K
    King David
    OVER 12 MILLION SHARES SHORT. GET READY FOR A RUN BACK OVER $3.00
  • M
    MBMoney
    Over the past month, Rigel has posted for 3 new territory manager positions, so they continue to add bodies in spite of a brutally bad 2022 for the company. If this management team presents poor results on the upcoming Q2 release, I'd be shocked if the board just continues to sit idle and allows the company to be run into the ground. At this point, while I have zero confidence in the team, I can't imagine that management would present negative results and expect to have any remaining credibility. Based on this alone, I'm wondering if they have something up their sleeve that might be positive leading up to or during the earnings call.
  • M
    MBMoney
    Interesting to see the patent grants that have been coming through for Rigel recently for RIP1 and Irak. Justia patent search lists them out.
  • G
    Gavin
    Can someone with a better understanding of phase 3 testing requirements explain to me some possible reasons why we have not heard the results (good or bad) from either the NIH or Imperial College studies on the effectiveness of fostamatinib on severely Ill patients? I understood the NIH trials were commenced in September and were started because of promising phase 2 results. I believe the Imperial College trials began in August of last year. The actual course of treatment and measurement for each trial was on the order of 60 days after administering the first dose. Even recognizing it takes time to enroll a sufficient number of patients, i would have expected results by now. Does it usually take a full year to complete phase 3 trials?
  • M
    MBMoney
    Barring something unforeseen, I guess the next order of business for Rigel is the Q2 earnings call in early August. The management team certainly hasn't instilled any confidence with investors, and I'm concerned about yet another dose of disappointing news. That said, perhaps the fact that Rigel deliberately tried to keep silent the deal with knight Therapeutics will allow us to 'back into' the approximate amount of up-front cash the company presumably received. Since nothing was announced about the deal, it was likely nothing substantial, but maybe it helped with some limitation on cash burn. It's hard to believe that the board of directors would sit back and continue to allow this team to fumble.
Advertisement
Advertisement